Kazia Therapeutics annual stock-based compensation
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Kazia Therapeutics Stock-Based Compensation Growth & History (KZIA)
Kazia Therapeutics's stock-based compensation was $653.2M for fiscal 2025.
View full Kazia Therapeutics company overviewKazia Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-06-30 | $653.2M | $120.6M | +22.64% |
| 2024 | 2024-06-30 | $532.6M | −$1.14B | −68.20% |
| 2023 | 2023-06-30 | $1.67B | $1.67B | +99900.00% |
| 2022 | 2022-06-30 | $1.7M | $1.0M | +163.14% |
| 2021 | 2021-06-30 | $636,383 | $374,278 | +142.80% |
| 2020 | 2020-06-30 | $262,105 | $15,718 | +6.38% |
| 2019 | 2019-06-30 | $246,387 | $81,165 | +49.12% |
| 2018 | 2018-06-30 | $165,222 | −$309,967 | −65.23% |
| 2017 | 2017-06-30 | $475,189 | $103,189 | +27.74% |
| 2016 | 2016-06-30 | $372,000 | — | — |
Kazia Therapeutics stock-based compensation trends
Over the last five fiscal years, Kazia Therapeutics's stock-based compensation increased from $262,105 to $653.2M, a change of $652.9M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Kazia Therapeutics source filings ↗